Transparency, Innovations, and Approvals in the Health Sector: Key Updates

The U.S. Food and Drug Administration's (FDA) protocols for accelerated drug approvals need greater transparency, according to the Institute for Clinical and Economic Review. The organization highlights the importance of using surrogate endpoints in approving drugs for serious, untreated conditions, emphasizing a need for clarity in these processes.

In a major development, the FDA approved the expanded use of Sparsentan for treating a rare kidney disorder. This positions the drug as the first to treat focal segmental glomerulosclerosis (FSGS), affecting the kidney's filtering units. Travere Therapeutics, the drug's maker, announced this milestone achievement on Monday.

Roche, driven by feedback from the European Medicines Agency, has initiated a new phase of its Elevidys gene therapy study. This move aims to generate additional data for treating Duchenne muscular dystrophy. The study comes in response to earlier scrutiny and patient deaths tied to the therapy.